Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Nature Communications|February 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trialSylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, et al.
Cancers|December 3, 2020
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa)Martin Eichler, Leopold Hentschel, Stephan Richter, et al.
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|April 23, 2024
Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centersSiyer Roohani, Felix Ehret, Marcus Beck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.
Oncology Research and Treatment|April 22, 2021
Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa StudyMartin Eichler, Dimosthenis Andreou, Henriette Golcher, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
International Journal of Cancer|October 10, 2020
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 7